Bone Defect Regeneration Using Mesenchymal Stem Cells from Bichat's Fat Pad.
Ostapets SV., Kosareva OS., Drovosekov MN., Nikitenko EV., Surovtseva MA., Kim II.
Animal Study with a reported sample of 120, published in Sovrem Tekhnologii Med (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Sovrem Tekhnologii Med (2026)
- Country
- Russia (Federation)
- Reported sample size
- 120
- Source database
- PubMed
- PMID
- 42524326
- DOI
- 10.17691/stm2026.18.3.04
Abstract (original English)
The aim of the study was to assess the efficiency of the mandibular bone defect regeneration by administering mesenchymal stem cells (MSC) from the Bichat's fat pad (B-MSC), as well as the osteoblasts differentiated from them, according to the morphological findings. The experimental study was carried out on male Wistar rats (n=120) aged 2 months, weighing 250-300 g. B-MSCs and the osteoblasts differentiated from them were used for the regeneration of rat mandibular bone defects formed by a round bur. In the control group, the defect was not filled, the defect was healing under the blood clot. The biopsy specimens were histologically examined on days 14, 30, and 90 after the injury formed. The infiltration of the bone defect site by inflammatory cells was revealed for all study groups 14 days after the injury. The groups with cell administration showed the resorption of bone trabeculae (B-MSC and osteoblast groups) and a large number of capillaries (an osteoblast group). On day 30 after the injury, the preparations of the groups with cell administration demonstrated a large number of capillaries (B-MSC and osteoblast groups) and primitive bone trabeculae with osteoblasts (an osteoblast group). Active osteoclastic resorption and inflammatory infiltration were revealed in the control group. The groups with cell administration 90 days after the injury, in contrast to the control g
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.